Skip to main content

Richard E. Pratley, MD

Richard E. Pratley, MD

Medical Director at the AdventHealth Diabetes Institute, Senior Investigator, Diabetes Program Lead at the Translational Research Institute

Translational Research, Infectious Disease

Pratley

Overview

Richard Pratley, MD, is a board-certified internal medicine physician and nationally recognized diabetes expert with advanced training in gerontology, geriatrics and clinical physiology and metabolism. He sees patients at AdventHealth Medical Group’s diabetes and endocrine specialty practice in Orlando and The Villages while also serving as the Medical Director of the AdventHealth Diabetes Institute and as a senior scientist in diabetes research for AdventHealth. He is a leading authority on new and emerging treatments for diabetes and its comorbidities, which is why many area physicians refer their patients to him for advanced diabetes care. Dr. Pratley earned his medical degree at Wayne State University in Detroit and undertook his residency at the University of Michigan. He next completed three consecutive fellowships in clinical physiology and metabolism, gerontology and geriatrics, and geriatrics at the National Institute on Aging in Baltimore, Johns Hopkins University and the University of Michigan, respectively.

Articles

Let's Be More Sensitive-How SGLT-2 Inhibitors and GLP-1 Receptor Agonists Affect beta-Cell Function in Type 2 Diabetes Comment on "Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM" by Ali et

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

2020

Genetic Discrimination Between LADA and Childhood-Onset Type 1 Diabetes Within the MHC

DIABETES CARE

2020

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses

BMJ OPEN

2020

Pharmacological therapies to address obesity in type 1 diabetes

CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY

2020

Characteristics of adult- compared to childhood-onset type 1 diabetes

DIABETIC MEDICINE

2020

Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes A Randomized Clinical Trial

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

2020

An improvement in skeletal muscle mitochondrial capacity with short-term aerobic training is associated with changes in Tribbles 1 expression

PHYSIOLOGICAL REPORTS

2020

Machine Learning to Identify Predictors of Glycemic Control in Type 2 Diabetes: An Analysis of Target HbA1c Reduction Using Empagliflozin/Linagliptin Data

PHARMACEUTICAL MEDICINE

2019

Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes

MOLECULAR METABOLISM

2019

Pioglitazone Therapy in Patients With Stroke and Prediabetes A Post Hoc Analysis of the IRIS Randomized Clinical Trial

JAMA NEUROLOGY

2019

Education & Training

Education

Wayne State University School of Medicine; University of Michigan- Ann Arbor; John Hopkins School of Medicine; University of Michigan - Dearborn

Residency

University of Michigan, Ann Arbor, MI

Fellowship

University of Michigan, Ann Arbor, MI; Johns Hopkins University, Baltimore, MD

Board Certifications

American Board of Internal Medicine

Associated Clinical Trials

NCT01942694

Vitamin D and Type 2 Diabetes

Icon for trial | Vitamin D and Type 2 Diabetes

Diabetes is a serious condition affecting about 1 in 10 people in the United States. Lifestyle changes, such as healthy eating, exercise and weight loss, can decrease the chances of developing diabetes. However, many people st ...

NCT01843127

A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects with Type 2 Diabetes Mellitus, Followed by An Open-label, Single-dose, Exenatide Active-control Period

Icon for trial | A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects with Type 2 Diabetes Mellitus, Followed by An Open-label, Single-dose, Exenatide

The primary purpose of this study is to understand the reasons why Ranolazine may potentially treat patients with T2DM. Ranolazine has been shown to block glucagon and therefore results in a lowering of blood glucose levels. Th ...

NCT01664624

A Phase 1b, Randomized, Double-Blind, Active Comparator (Open-Label Exenatide) Controlled Study to Evaluate the Effect of Roflumilast Plus Alogliptin on Postprandial Active GLP-1 Level and 24-hour Glucose Level in Subjects with Type 2 Diabetes Who Are Inadequately Controlled on a Stable Dose of Metformin

Icon for trial | A Phase 1b, Randomized, Double-Blind, Active Comparator (Open-Label Exenatide) Controlled Study to Evaluate the Effect of Roflumilast Plus Alogliptin on Postprandial Active GLP-1 Level and 24-hour Glucose Level in Subjects with Type 2 Diabetes Who Are Ina

You are being asked to participate in this study because you have type 2 diabetes and are being treated with metformin. Despite the availability of several different classes of medications to treat the diabetes, many patients a ...

NCT04016662

A Randomized Cross-over Trial Evaluating Automated Insulin Delivery Technologies on Hypoglycemia and Quality of Life in Elderly Adults with Type 1 Diabetes (Automated Insulin Delivery in Elderly with Type 1 Diabetes [AIDE t1D])

Icon for trial | AIDE: A Randomized Cross-Over Trial Evaluating Automated Insulin Delivery (AID) Technologies on Hypoglycemia and Quality of Life (QOL) in Elderly Adults with Type 1 Diabetes (T1D)

This study is currently enrolling.

To determine how safe and effective hybrid closed-loop and predictive low glucose suspend insulin pump technologies are for patients aged 65 and older with type 1 diabetes, and learn the effect they have on hypoglycemia in this ...

Researching Covid Outcomes in Diabetes (RECODE)

Icon for trial | Researching Covid Outcomes in Diabetes (RECODE)

This study is currently enrolling.

We invite you to take part in a research study because you have previously had a confirmed diagnosis for COVID-19 (the new coronavirus) disease. You have recovered, or are recovering from this disease, with no fever or cough wi ...